Base Pair Biotechnologies

Base Pair Biotechnologies is a private, US-based biotech firm focused on aptamer discovery and development. The company employs a consultative, project-based business model, offering services from initial target consultation through functional aptamer testing and optimization. Its core technology includes a multiplexed SELEX platform and proprietary bioinformatics for selecting aptamers against challenging targets, including small molecules and toxins. While primarily a service provider, the company is actively exploring the therapeutic and diagnostic potential of aptamers, indicating a platform with potential for internal asset development.

Proprietary aptamer discovery platform featuring Multiplex SELEX™ for parallel selection against up to 30 targets, integrated next-generation sequencing, and AI/bioinformatics for candidate identification and optimization. Focus on challenging targets like small molecules and toxins.

Base Pair competes in the niche aptamer discovery sector against other specialized biotechs (e.g., Aptamer Group, Aptus Biotech) and the service offerings of some academic tech transfer offices. It also competes indirectly with the vast antibody industry and CROs offering antibody generation services. Its differentiation lies in its multiplexed selection capability, strong bioinformatics integration, and focus on solving particularly challenging target problems.